Bioceres Crop Solutions Future Growth
Future criteria checks 4/6
Bioceres Crop Solutions is forecast to grow earnings and revenue by 43% and 9.6% per annum respectively while EPS is expected to grow by 41.5% per annum.
Key information
43.0%
Earnings growth rate
41.5%
EPS growth rate
Chemicals earnings growth | 15.9% |
Revenue growth rate | 9.6% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 28 Jan 2025 |
Recent future growth updates
Recent updates
Bioceres Is Getting Cheaper, Not Yet An Opportunity But More Interesting
Nov 13Take Care Before Jumping Onto Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Even Though It's 29% Cheaper
Sep 28Bioceres' Q4 2024 Shows Challenges With HB4 Rollout, Still A Hold Despite Lower Stock Prices
Sep 17These 4 Measures Indicate That Bioceres Crop Solutions (NASDAQ:BIOX) Is Using Debt Extensively
Aug 03Bioceres Needs To Add Clarity Around Borrowings
Mar 23Bioceres Crop Solutions (NASDAQ:BIOX) Takes On Some Risk With Its Use Of Debt
Feb 03Does Bioceres Crop Solutions (NASDAQ:BIOX) Have A Healthy Balance Sheet?
Oct 04Bioceres Crop Solutions Corp.'s (NASDAQ:BIOX) Popularity With Investors Is Clear
Jun 21Here's Why Bioceres Crop Solutions (NASDAQ:BIOX) Is Weighed Down By Its Debt Load
May 09Bioceres: A Resilient Small Cap With Conference Appearances After Thursday's Earnings
Sep 06Bioceres Crop Solutions jumps 15% after investor pitch
Aug 23We Think Bioceres Crop Solutions (NASDAQ:BIOX) Is Taking Some Risk With Its Debt
Apr 10Bioceres Has Not Resolved Its Major Risks And Is Growing Based On Commodities Bullishness
Mar 31Is Now The Time To Look At Buying Bioceres Crop Solutions Corp. (NASDAQ:BIOX)?
Mar 17Is Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Trading At A 21% Discount?
Nov 13Bioceres Crop Solutions (NASDAQ:BIOX) Shareholders Will Want The ROCE Trajectory To Continue
Jul 08Estimating The Intrinsic Value Of Bioceres Crop Solutions Corp. (NASDAQ:BIOX)
Jun 16What Does Bioceres Crop Solutions Corp.'s (NASDAQ:BIOX) Share Price Indicate?
May 26Bioceres partners with Havanna to offer consumers HB4 wheat-based sustainable products
May 10Does Bioceres Crop Solutions (NASDAQ:BIOX) Have A Healthy Balance Sheet?
May 05Bioceres Crop Solutions (NYSEMKT:BIOX) Shareholders Will Want The ROCE Trajectory To Continue
Apr 05Are Investors Undervaluing Bioceres Crop Solutions Corp. (NYSEMKT:BIOX) By 22%?
Mar 10Bioceres Crop Solutions (NYSEMKT:BIOX) Shareholders Booked A 53% Gain In The Last Year
Feb 12Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
6/30/2027 | 571 | 55 | 32 | 55 | 1 |
6/30/2026 | 508 | 29 | 49 | 54 | 3 |
6/30/2025 | 462 | 10 | 49 | 65 | 4 |
9/30/2024 | 441 | 1 | 12 | 32 | N/A |
6/30/2024 | 465 | 3 | 19 | 42 | N/A |
3/31/2024 | 446 | 3 | -13 | 10 | N/A |
12/31/2023 | 455 | 22 | 6 | 30 | N/A |
9/30/2023 | 409 | 14 | 26 | 50 | N/A |
6/30/2023 | 419 | 19 | -20 | 3 | N/A |
3/31/2023 | 416 | 15 | -12 | 6 | N/A |
12/31/2022 | 391 | -19 | -3 | 11 | N/A |
9/30/2022 | 389 | -8 | -47 | -36 | N/A |
6/30/2022 | 328 | -7 | -27 | -18 | N/A |
3/31/2022 | 308 | -2 | -1 | 9 | N/A |
12/31/2021 | 275 | 4 | -12 | -2 | N/A |
9/30/2021 | 231 | 1 | -27 | -12 | N/A |
6/30/2021 | 207 | -7 | -20 | -6 | N/A |
3/31/2021 | 174 | -5 | -36 | -24 | N/A |
12/31/2020 | 164 | -7 | -24 | -13 | N/A |
9/30/2020 | 178 | 3 | -9 | -4 | N/A |
6/30/2020 | 172 | 3 | 5 | 9 | N/A |
3/31/2020 | 174 | 0 | 14 | 18 | N/A |
12/31/2019 | 167 | -18 | 28 | 32 | N/A |
9/30/2019 | 167 | -23 | 18 | 22 | N/A |
6/30/2019 | 160 | -18 | 26 | 30 | N/A |
3/31/2019 | 142 | -26 | 29 | 33 | N/A |
12/31/2018 | 145 | -8 | 22 | 27 | N/A |
9/30/2018 | 129 | -13 | 31 | 37 | N/A |
6/30/2018 | 133 | -11 | N/A | 18 | N/A |
6/30/2017 | 94 | -12 | N/A | 19 | N/A |
12/31/2016 | 41 | -6 | N/A | -1 | N/A |
12/31/2015 | 5 | -1 | N/A | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BIOX's forecast earnings growth (43% per year) is above the savings rate (2.6%).
Earnings vs Market: BIOX's earnings (43% per year) are forecast to grow faster than the US market (15% per year).
High Growth Earnings: BIOX's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: BIOX's revenue (9.6% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: BIOX's revenue (9.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BIOX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/30 10:41 |
End of Day Share Price | 2025/01/30 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bioceres Crop Solutions Corp. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Brian Kemp Dolliver | Brookline Capital Markets |
Austin Moeller | Canaccord Genuity |
Benjamin Klieve | Lake Street Capital Markets, LLC |